{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:02:10Z","timestamp":1790002930961,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.urolonc.2011.12.001","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T06:23:45Z","timestamp":1327991025000},"page":"303-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Fibroblast growth factor receptor-3 in urothelial tumorigenesis"],"prefix":"10.1016","volume":"31","author":[{"given":"Gopa","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2011.12.001_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2011.12.001_bib2","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2011.12.001_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4238\/vol10-1gmr923","article-title":"Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer genetics and molecular research","volume":"10","author":"Dodurga","year":"2011","journal-title":"GMR"},{"key":"10.1016\/j.urolonc.2011.12.001_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00345-003-0377-5","article-title":"Occupational exposure and urological cancer","volume":"21","author":"Golka","year":"2004","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib5","first-page":"31","article-title":"Superficial bladder cancer: An update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","article-title":"Urothelial tumorigenesis: A tale of divergent pathways","volume":"5","author":"Wu","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2011.12.001_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jcb.240501305","article-title":"Bladder cancer from a perspective of 40 years","volume":"16I","author":"Koss","year":"1992","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.urolonc.2011.12.001_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(93)91595-D","article-title":"Genetic alterations in bladder cancer","volume":"342","author":"Dalbagni","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2011.12.001_bib9","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/ijc.21958","article-title":"Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder","volume":"119","author":"van Oers","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2011.12.001_bib10","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.onc.1204315","article-title":"Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation","volume":"20","author":"Zhang","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2011.12.001_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2011.12.001_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOU.0b013e3283097889","article-title":"Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signaling pathways","volume":"18","author":"Wallerand","year":"2008","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/carcin\/bgi310","article-title":"Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?","volume":"27","author":"Knowles","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2011.12.001_bib14","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.ejhg.5200883","article-title":"Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders","volume":"10","author":"van Rhijn","year":"2002","journal-title":"European J Hum Genet EJHG"},{"key":"10.1016\/j.urolonc.2011.12.001_bib16","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1128\/MCB.17.10.5739","article-title":"Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain","volume":"17","author":"Webster","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgi290","article-title":"Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b","volume":"27","author":"Bernard-Pierrot","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2011.12.001_bib18","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2141.2002.03618.x","article-title":"A molecular study of the t(4;14) in multiple myeloma","volume":"118","author":"Sibley","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/hmg\/ddi127","article-title":"Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans","volume":"14","author":"Logie","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.urolonc.2011.12.001_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2004.11.012","article-title":"Cell responses to FGFR3 signaling: Growth, differentiation, and apoptosis","volume":"304","author":"L'Hote","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib21","first-page":"82","article-title":"Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities","volume":"12","author":"Werner","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib22","doi-asserted-by":"crossref","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","article-title":"Receptor specificity of the fibroblast growth factor family","volume":"271","author":"Ornitz","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2011.12.001_bib23","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","article-title":"Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer","volume":"26","author":"Tomlinson","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2011.12.001_bib24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00345-007-0213-4","article-title":"Role of FGFR3 in urothelial cell carcinoma: Biomarker and potential therapeutic target","volume":"25","author":"Knowles","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/j.1460-2075.1996.tb00384.x","article-title":"Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia","volume":"15","author":"Webster","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.urolonc.2011.12.001_bib26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jmb.2005.11.077","article-title":"FGFR3 dimer stabilization due to a single amino acid pathogenic mutation","volume":"356","author":"Li","year":"2006","journal-title":"J Mol Biol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib27","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib28","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1200\/JCO.2003.05.073","article-title":"Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome","volume":"21","author":"van Rhijn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib29","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas","volume":"24","author":"Hernandez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib30","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1158\/1078-0432.CCR-05-0122","article-title":"FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis","volume":"11","author":"Hernandez","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib31","first-page":"967","article-title":"Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and\/or non-invasive lesions","volume":"12","author":"Matsumoto","year":"2004","journal-title":"Oncol Reports"},{"key":"10.1016\/j.urolonc.2011.12.001_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejso.2005.11.018","article-title":"FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer","volume":"32","author":"Mhawech-Fauceglia","year":"2006","journal-title":"Eur J Surgical Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth","volume":"11","author":"Gomez-Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib35","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2011.12.001_bib36","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"Lopez-Knowles","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-Year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib38","first-page":"281","article-title":"Bacillus calmette-guerin failures and beyond: Contemporary management of non-muscle-invasive bladder cancer","volume":"10","author":"Grossman","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib40","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1464-410X.2008.07980.x","article-title":"Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer","volume":"102","author":"Milowsky","year":"2008","journal-title":"BJU international"},{"key":"10.1016\/j.urolonc.2011.12.001_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib42","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib43","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3747\/co.v18i1.695","article-title":"First- and second-line therapy for metastatic urothelial carcinoma of the bladder","volume":"18","author":"Yafi","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib44","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2011.12.001_bib45","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1158\/1078-0432.CCR-05-0282","article-title":"Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation","volume":"11","author":"Martinez-Torrecuadrada","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"Qing","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2011.12.001_bib47","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2011.12.001_bib48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-&;\u03b1 treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2011.12.001_bib49","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2011.12.001_bib50","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2011.12.001_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2011.12.001_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2011.12.001_bib53","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-10-3650","article-title":"Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma","volume":"103","author":"Trudel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2011.12.001_bib54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/jpet.109.162768","volume":"332","author":"Miyake","year":"2010","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.urolonc.2011.12.001_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2011.12.001_bib56","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Research"},{"key":"10.1016\/j.urolonc.2011.12.001_bib57","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-05-0358","article-title":"CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia","volume":"11","author":"Lopes de Menezes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib58","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/1078-0432.CCR-07-1466","article-title":"A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"14","author":"Sarker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.12.001_bib59","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.3563","article-title":"TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I\/II dose finding and biomarker study","volume":"27","author":"Angevin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.2892","article-title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma","volume":"224","author":"Al-Ahmadie","year":"2011","journal-title":"Journal Pathol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.urolonc.2005.11.023","article-title":"Molecular markers in bladder cancer: A critical appraisal","volume":"24","author":"Konety","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2011.12.001_bib62","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nm0697-621","article-title":"Detection of bladder cancer recurrence by microsatellite analysis of urine","volume":"3","author":"Steiner","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2011.12.001_bib63","first-page":"257","article-title":"Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine","volume":"9","author":"van Rhijn","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911004613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911004613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:58:45Z","timestamp":1761040725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143911004613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1078143911004613"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.12.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor receptor-3 in urothelial tumorigenesis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}